Skip to main content
Fig. 7 | Alzheimer's Research & Therapy

Fig. 7

From: Serotonin augmentation therapy by escitalopram has minimal effects on amyloid-β levels in early-stage Alzheimer’s-like disease in mice

Fig. 7

Levels of soluble amyloid precursor protein α (sAPPα) and sAPPβ in the brain of 5,7-dihydroxytryptamine (DHT)-lesioned APPSWE/PS1ΔE9 (APP/PS1) mice. Levels of sAPPα and sAPPβ in the neocortex (a, c) and hippocampus (b, d) of APP/PS1 mice after sham treatment and DHT-induced lesioning were measured by Meso Scale Discovery multiplex analysis. Data are presented as mean ± SEM and were analysed by unpaired, two-tailed Mann-Whitney U test. *p < 0.05

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193